

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Cardiovascular health and the menopausal woman: the... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1576/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1576" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment" />
    
            <meta name="og:title" content="F1000Research Article: Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment.">
            <meta name="og:description" content="Read the latest article version by Frederick Naftolin, Jenna Friedenthal, Richard Nachtigall, Lila Nachtigall, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16960">
            <meta name="article-id" content="15548">
            <meta name="dc.title" content="Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment">
            <meta name="dc.description" content="Reports have correlated the use of estrogen for the treatment of menopausal symptoms with beneficial effects on the cardiovascular system. Molecular, biochemical, preclinical, and clinical studies have furnished a wealth of evidence in support of this outcome of estrogen action. The prospective randomized Women&rsquo;s Health Initiative (WHI) and the Early Versus Late Intervention Trial (ELITE) showed that starting menopausal hormone treatment (MHT) within 5 to 10 years of menopause is fundamental to the success of estrogen&rsquo;s cardioprotection in post-menopausal women without adverse effects. Age stratification of the WHI data has shown that starting hormone treatment within the first decade after menopause is both safe and effective, and the long-term WHI follow-up studies are supportive of cardioprotection. This is especially true in estrogen-treated women who underwent surgical menopause. A critique of the WHI and other relevant studies is presented, supporting that the timely use of estrogens protects against age- and hormone-related cardiovascular complications. Salutary long-term hormone treatment for menopausal symptoms and prevention of complications has been widely reported, but there are no prospective trials defining the correct length to continue MHT. At present, women undergoing premature menopause receive estrogen treatment (ET) until evidence of hormone-related complications intervenes. Normal women started on MHT who receive treatment for decades without hormone-related complications have been reported, and the WHI follow-up studies are promising of long-term post-treatment cardioprotection. A prevention-based holistic approach is proposed for timely and continuing MHT/ET administration as part of the general management of the menopausal woman. But this should be undertaken only with scheduled, annual patient visits including evaluations of cardiovascular status. Because of the continued occurrence of reproductive cancers well into older ages, these visits should include genital and breast cancer screening.">
            <meta name="dc.subject" content="estrogen, estradiol, menopause, heart disease, cardioprotection, Timing Hypothesis">
            <meta name="dc.creator" content="Naftolin, Frederick">
            <meta name="dc.creator" content="Friedenthal, Jenna">
            <meta name="dc.creator" content="Nachtigall, Richard">
            <meta name="dc.creator" content="Nachtigall, Lila">
            <meta name="dc.date" content="2019/09/03">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15548.1">
            <meta name="dc.source" content="F1000Research 2019 8:1576">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="estrogen">
            <meta name="prism.keyword" content="estradiol">
            <meta name="prism.keyword" content="menopause">
            <meta name="prism.keyword" content="heart disease">
            <meta name="prism.keyword" content="cardioprotection">
            <meta name="prism.keyword" content="Timing Hypothesis">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/09/03">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1576">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15548.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1576">
            <meta name="citation_title" content="Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment">
            <meta name="citation_abstract" content="Reports have correlated the use of estrogen for the treatment of menopausal symptoms with beneficial effects on the cardiovascular system. Molecular, biochemical, preclinical, and clinical studies have furnished a wealth of evidence in support of this outcome of estrogen action. The prospective randomized Women&rsquo;s Health Initiative (WHI) and the Early Versus Late Intervention Trial (ELITE) showed that starting menopausal hormone treatment (MHT) within 5 to 10 years of menopause is fundamental to the success of estrogen&rsquo;s cardioprotection in post-menopausal women without adverse effects. Age stratification of the WHI data has shown that starting hormone treatment within the first decade after menopause is both safe and effective, and the long-term WHI follow-up studies are supportive of cardioprotection. This is especially true in estrogen-treated women who underwent surgical menopause. A critique of the WHI and other relevant studies is presented, supporting that the timely use of estrogens protects against age- and hormone-related cardiovascular complications. Salutary long-term hormone treatment for menopausal symptoms and prevention of complications has been widely reported, but there are no prospective trials defining the correct length to continue MHT. At present, women undergoing premature menopause receive estrogen treatment (ET) until evidence of hormone-related complications intervenes. Normal women started on MHT who receive treatment for decades without hormone-related complications have been reported, and the WHI follow-up studies are promising of long-term post-treatment cardioprotection. A prevention-based holistic approach is proposed for timely and continuing MHT/ET administration as part of the general management of the menopausal woman. But this should be undertaken only with scheduled, annual patient visits including evaluations of cardiovascular status. Because of the continued occurrence of reproductive cancers well into older ages, these visits should include genital and breast cancer screening.">
            <meta name="citation_description" content="Reports have correlated the use of estrogen for the treatment of menopausal symptoms with beneficial effects on the cardiovascular system. Molecular, biochemical, preclinical, and clinical studies have furnished a wealth of evidence in support of this outcome of estrogen action. The prospective randomized Women&rsquo;s Health Initiative (WHI) and the Early Versus Late Intervention Trial (ELITE) showed that starting menopausal hormone treatment (MHT) within 5 to 10 years of menopause is fundamental to the success of estrogen&rsquo;s cardioprotection in post-menopausal women without adverse effects. Age stratification of the WHI data has shown that starting hormone treatment within the first decade after menopause is both safe and effective, and the long-term WHI follow-up studies are supportive of cardioprotection. This is especially true in estrogen-treated women who underwent surgical menopause. A critique of the WHI and other relevant studies is presented, supporting that the timely use of estrogens protects against age- and hormone-related cardiovascular complications. Salutary long-term hormone treatment for menopausal symptoms and prevention of complications has been widely reported, but there are no prospective trials defining the correct length to continue MHT. At present, women undergoing premature menopause receive estrogen treatment (ET) until evidence of hormone-related complications intervenes. Normal women started on MHT who receive treatment for decades without hormone-related complications have been reported, and the WHI follow-up studies are promising of long-term post-treatment cardioprotection. A prevention-based holistic approach is proposed for timely and continuing MHT/ET administration as part of the general management of the menopausal woman. But this should be undertaken only with scheduled, annual patient visits including evaluations of cardiovascular status. Because of the continued occurrence of reproductive cancers well into older ages, these visits should include genital and breast cancer screening.">
            <meta name="citation_keywords" content="estrogen, estradiol, menopause, heart disease, cardioprotection, Timing Hypothesis">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Frederick Naftolin">
            <meta name="citation_author_institution" content="Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA">
            <meta name="citation_author" content="Jenna Friedenthal">
            <meta name="citation_author_institution" content="Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA">
            <meta name="citation_author" content="Richard Nachtigall">
            <meta name="citation_author_institution" content="Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA">
            <meta name="citation_author" content="Lila Nachtigall">
            <meta name="citation_author_institution" content="Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA">
            <meta name="citation_publication_date" content="2019/09/03">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1576">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15548.1">
            <meta name="citation_firstpage" content="1576">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1576/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1576.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16960 /> <input type=hidden id=articleId name=articleId value=15548 /> <input type=hidden id=xmlUrl value="/articles/8-1576/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1576-v1.xml"> <input type=hidden id=article_uuid value=cc9fba0b-e981-42d7-9a37-f0aa6917127a /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15548.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15548.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1576"
  },
  "headline": "Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone...",
  "datePublished": "2019-09-03T14:20:24",
  "dateModified": "2019-09-03T14:20:24",
  "author": [
    {
      "@type": "Person",
      "name": "Frederick Naftolin"
    },    {
      "@type": "Person",
      "name": "Jenna Friedenthal"
    },    {
      "@type": "Person",
      "name": "Richard Nachtigall"
    },    {
      "@type": "Person",
      "name": "Lila Nachtigall"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Reports have correlated the use of estrogen for the treatment of menopausal symptoms with beneficial effects on the cardiovascular system. Molecular, biochemical, preclinical, and clinical studies have furnished a wealth of evidence in support of this outcome of estrogen action. The prospective randomized Women&rsquo;s Health Initiative (WHI) and the Early Versus Late Intervention Trial (ELITE) showed that starting menopausal hormone treatment (MHT) within 5 to 10 years of menopause is fundamental to the success of estrogen&rsquo;s cardioprotection in post-menopausal women without adverse effects. Age stratification of the WHI data has shown that starting hormone treatment within the first decade after menopause is both safe and effective, and the long-term WHI follow-up studies are supportive of cardioprotection. This is especially true in estrogen-treated women who underwent surgical menopause. A critique of the WHI and other relevant studies is presented, supporting that the timely use of estrogens protects against age- and hormone-related cardiovascular complications. Salutary long-term hormone treatment for menopausal symptoms and prevention of complications has been widely reported, but there are no prospective trials defining the correct length to continue MHT. At present, women undergoing premature menopause receive estrogen treatment (ET) until evidence of hormone-related complications intervenes. Normal women started on MHT who receive treatment for decades without hormone-related complications have been reported, and the WHI follow-up studies are promising of long-term post-treatment cardioprotection. A prevention-based holistic approach is proposed for timely and continuing MHT/ET administration as part of the general management of the menopausal woman. But this should be undertaken only with scheduled, annual patient visits including evaluations of cardiovascular status. Because of the continued occurrence of reproductive cancers well into older ages, these visits should include genital and breast cancer screening."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1576.html",
            "name": "Cardiovascular health and the menopausal woman: the role of estrogen..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Cardiovascular health and the menopausal woman: the role of estrogen... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16960 data-id=15548 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15548.1" data-recommended="" data-doi="10.12688/f1000research.15548.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1576/v1/pdf?article_uuid=cc9fba0b-e981-42d7-9a37-f0aa6917127a" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15548-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15548-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15548-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Naftolin F, Friedenthal J, Nachtigall R and Nachtigall L. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1576 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15548.1" target=_blank>https://doi.org/10.12688/f1000research.15548.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15548-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15548 id=track-article-signin-15548 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15548?target=/articles/8-1576.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16960 /> <input name=articleId type=hidden value=15548 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:frederick.naftolin@nyumc.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Frederick Naftolin</span></a><a href="https://orcid.org/0000-0002-9447-6266" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9447-6266</div>,&nbsp;</span><span class="">Jenna Friedenthal,&nbsp;</span><span class="">Richard Nachtigall,&nbsp;</span><span class="">Lila Nachtigall</span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:frederick.naftolin@nyumc.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Frederick Naftolin</span></a><a href="http://orcid.org/0000-0002-9447-6266" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9447-6266</div>,&nbsp;</span><span class="">Jenna Friedenthal,&nbsp;</span><span class="">Richard Nachtigall,&nbsp;</span><span class="">Lila Nachtigall</span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 03 Sep 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15548.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA<br/> <p> <div class=margin-bottom> Frederick Naftolin <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Jenna Friedenthal <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Richard Nachtigall <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Lila Nachtigall <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55795-52749></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55796-52748></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=55797-52750></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Reports have correlated the use of estrogen for the treatment of menopausal symptoms with beneficial effects on the cardiovascular system. Molecular, biochemical, preclinical, and clinical studies have furnished a wealth of evidence in support of this outcome of estrogen action. The prospective randomized Womens Health Initiative (WHI) and the Early Versus Late Intervention Trial (ELITE) showed that starting menopausal hormone treatment (MHT) within 5 to 10 years of menopause is fundamental to the success of estrogens cardioprotection in post-menopausal women without adverse effects. Age stratification of the WHI data has shown that starting hormone treatment within the first decade after menopause is both safe and effective, and the long-term WHI follow-up studies are supportive of cardioprotection. This is especially true in estrogen-treated women who underwent surgical menopause. A critique of the WHI and other relevant studies is presented, supporting that the timely use of estrogens protects against age- and hormone-related cardiovascular complications. Salutary long-term hormone treatment for menopausal symptoms and prevention of complications has been widely reported, but there are no prospective trials defining the correct length to continue MHT. At present, women undergoing premature menopause receive estrogen treatment (ET) until evidence of hormone-related complications intervenes. Normal women started on MHT who receive treatment for decades without hormone-related complications have been reported, and the WHI follow-up studies are promising of long-term post-treatment cardioprotection. A prevention-based holistic approach is proposed for timely and continuing MHT/ET administration as part of the general management of the menopausal woman. But this should be undertaken only with scheduled, annual patient visits including evaluations of cardiovascular status. Because of the continued occurrence of reproductive cancers well into older ages, these visits should include genital and breast cancer screening. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> estrogen, estradiol, menopause, heart disease, cardioprotection, Timing Hypothesis </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Frederick Naftolin (<a href="mailto:frederick.naftolin@nyumc.org">frederick.naftolin@nyumc.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Frederick Naftolin </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Naftolin F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Naftolin F, Friedenthal J, Nachtigall R and Nachtigall L. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1576 (<a href="https://doi.org/10.12688/f1000research.15548.1" target=_blank>https://doi.org/10.12688/f1000research.15548.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 03 Sep 2019, <b>8</b>(F1000 Faculty Rev):1576 (<a href="https://doi.org/10.12688/f1000research.15548.1" target=_blank>https://doi.org/10.12688/f1000research.15548.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 03 Sep 2019, <b>8</b>(F1000 Faculty Rev):1576 (<a href="https://doi.org/10.12688/f1000research.15548.1" target=_blank>https://doi.org/10.12688/f1000research.15548.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e176>Introduction</h2><p class="" id=d21666e179>The age-related cessation of ovarian follicle development and surgical removal of the ovaries are followed by dramatic declines of circulating estrogens, especially estradiol. Depending on the individual woman, the decline of circulating estrogen is followed by numerous signs and symptoms of estrogen deficiency: vasomotor episodes, sleep disorders, depression, metabolic imbalance, diminished bone mineral mass, and decreased skin turgor, to enumerate the most well-known symptoms and complications of menopause<sup><a href="#ref-1">1</a></sup>. These effects of decreased estrogen are commonly and successfully treated with menopausal hormone treatment (MHT): estrogen alone for women who have had their ovaries and uterus removed (estrogen treatment, or ET) or estrogen plus a progestin for those whose endometrium remains. The results are generally very prompt and satisfactory.</p><p class="" id=d21666e186>If the MHT is begun within the first few years after menopause, the benefits far outweigh the risks for most women. This has been shown to be an effective pharmacological approach to post menopausal health<sup><a href="#ref-2">2</a></sup>. This review concerns an associated and controversial issue in womens health: the possible cardioprotective value of estrogen administration in menopausal women and how the lessons learned in testing for this additional positive effect of MHT have better delineated prevention as a lifelong approach to womens wellness. It does not address the management of established cardiac disease, such as cardiac failure.</p><p class="" id=d21666e193>As will be seen, although the evidence favors cardioprotective effects of timely estrogen administration of the post-menopausal woman, the final proofprospective evidence of reduced cardiac eventsremains to be obtained. Without such final proof, the inclusion of cardioprevention as the justification for MHT is not warranted. Rather, it is prudent to develop an approach to the management of the post-menopausal woman that is founded on patient education, lifestyle modification, and treatment that includes MHT/ET in a way that offers the possible added value of cardioprotection without conferring the additional burden of unwanted side effects<sup><a href="#ref-3">3</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e203>Estrogen and cardioprotection</h2><p class="" id=d21666e206>For more than 50 years, estrogen has been considered cardioprotective. The first suggestions arose from sex differences in clinical presentation of myocardial symptoms and events; angina and infarction appear about a decade earlier in men than in women<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. Since womens cardiac events usually followed the cessation of ovarian function (natural or induced menopause) (<a href="#f1">Figure 1</a>), it has been proposed that the loss of estrogen was causal and that the roughly 10-year hiatus reflected the effects on the cardiovascular system of the loss of estrogen-secreting ovarian follicles<sup><a href="#ref-6">6</a></sup>. Epidemiological studies have supported this idea<sup><a href="#ref-7">7</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure1.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure1.gif"></a><div class=caption><h3>Figure 1. Prevalence of carotid atherosclerosis by age and sex.</h3><p id=d21666e237>Reprinted from Joakimsen <i>et al</i>.<sup><a href="#ref-14">14</a></sup> with permission.</p></div></div><p class="" id=d21666e251>There are myriad proposed mechanisms by which endogenous estrogen may protect against cardiovascular disease (CVD). One proposed mechanism is that estrogen administration has a known positive impact on plasma lipid profiles, anti-platelet effects, and anti-oxidant effects<sup><a href="#ref-8">8</a><a href="#ref-10">10</a></sup>. Previous studies have shown that post-menopausal women experience greater arterial stiffening, a known marker of vascular aging, than pre-menopausal women<sup><a href="#ref-11">11</a></sup>, and a study by Moreau <i>et al</i>. suggests that estrogen improves endothelial-dependent vasodilatation<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d21666e272>Estrogen receptors and aromatase are present in human coronary artery endothelium<sup><a href="#ref-13">13</a></sup>. Estrogen receptors have profound action on muscles and insulin action, both of which are necessary for maintenance of vessels<sup><a href="#ref-15">15</a></sup>. Abnormalities of estrogen receptor alpha have been linked to CVD<sup><a href="#ref-16">16</a></sup>. Abnormalities of aromatase are rare, probably due to the requirement for aromatase during reproduction, and have been associated with early atherogenesis<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>.</p><p class="" id=d21666e295>Estradiol has also been shown to inhibit monocyte adhesion to vascular endothelium, a known step in the development of atheromas and arteriosclerosis<sup><a href="#ref-19">19</a></sup>. Evidence now suggests that this process is mediated by sex steroidinduced inhibition (more specifically, sialylation) of neural cell adhesion molecules (nCAMs), which are among the early arresting mechanisms for capturing leukocytes in areas of inflammation; sex steroidinduced sialylation of nCAM molecules prevented attachment of monocytes to endothelial cells<sup><a href="#ref-20">20</a></sup>. Similar effects on leukocyte capture by hormonal manipulation, but not directly related to cardioprotection have been published<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e316>Many clinical studies support the cardioprotective effects of estrogen treatment on the incidence/progression of cardiovascular disease in estrogen-deficient women</h2><p class="" id=d21666e319>Contrary to the prevalent understanding among patients and clinicians, the Womens Health Initiative (WHI) has shown that when administered to menopausal women between 50 and 54 years of age, ET is clearly cardioprotective<sup><a href="#ref-23">23</a></sup>. However, the roll-out of this data over the years has been confusing (see below).</p><p class="" id=d21666e326>On the contrary, the Nurses Health Study (NHS), one of the largest ongoing observational studies of women (59,337 ongoing subjects), has been very clear. In its latest review of cardioprotection the NHS continued to show a highly significant decrease in the relative risk of major coronary diseaseodds ratio 0.45, confidence interval (CI) 0.340.60in women who received MHT<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. Langers<sup><a href="#ref-26">26</a></sup> review of the results of 10 observational studies showed that, in all studies except one, MHT reduced the risk of CVD, and several studies showed marked reduction on cardiovascular risk<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Other publications based on reviews of recent observational studies, including the effect of menopausal age or MHT on heart failure, have not shown a definitive role of estrogen, nor of MHT, in outcomes<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>.</p><p class="" id=d21666e354>A large Bayesian analysis by Salpeter <i>et al</i>. included both premature and natural menopausal women<sup><a href="#ref-7">7</a></sup>. It makes a strong case for estrogen protection against cardiovascular complications, especially among post-ovariectomy women, in those who receive estrogen immediately following surgical menopause<sup><a href="#ref-7">7</a></sup>. In addition, the same group has shown the cost-effectiveness of ET in young menopausal women taking estrogen for 5 to 30 years<sup><a href="#ref-31">31</a></sup>. The first retrospective study of both carotid intima-media thickness (CIMT) and coronary artery calcium (CAC) showed that post-menopausal women taking MHT had statistically significant protection compared with non-treated controls<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d21666e376>In addition to pioneering epidemiological studies supporting estrogen, Hodis, Mack and Lobo have shown, in the prospective randomized Early Versus Late Intervention Trial (ELITE), that ET inhibits the progress of imaging markers of CVD<sup><a href="#ref-33">33</a></sup> (see below). Aspects of the effects of MHT, including the role of the progestins, other than cardiovascular effects were reviewed by Lobo <i>et al</i>.<sup><a href="#ref-33">33</a></sup> and will not be covered in this contribution.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e393>Two large randomized clinical trials initially furnished negative results that have been corrected by improved interpretation and further research</h2><p class="" id=d21666e396>The WHIs initial repudiation of the cardioprotective effects of estrogen has driven the confirmation of the beneficial use and safety of both ET and MHT and furnished evidence of the importance of the timing of the start of MHT.</p><p class="" id=d21666e399>Over the past two decades, the cardioprotective effects of estrogen have been questioned, largely by the interpretation of the results of two large, National Institutes of Healthsponsored randomized clinical trials: the Heart and Estrogen/Progestin Replacement Study (HERS)<sup><a href="#ref-34">34</a></sup> and the WHI<sup><a href="#ref-35">35</a></sup>. Both studies showed increased cardiovascular events during the first year of hormone treatment (HT). These studies drew great attention because of their large numbers of subjects and their report of early harm (increased venous thromboembolism, or VTE) from the use of MHT/ET<sup><a href="#ref-36">36</a></sup>. In fact, the adverse outcomes in the first years of the HERS and WHI appear to be traceable to the higher incidence of estrogen-induced VTE in subjects at higher risk than the normal population<sup><a href="#ref-37">37</a></sup>. We and others have addressed the causes of these unexpected findings and why the unstratified for age report of the WHI<sup><a href="#ref-35">35</a></sup> did not represent findings in women who received treatment for early post-menopausal symptoms<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. To be more precise, in the HERS trial of what was termed secondary cardio-prevention by estrogen, all subjects had active clinical CVD (myocardial infarctions/intractable angina pectoris) and were prone to VTE<sup><a href="#ref-35">35</a></sup>. The subjects received continuous combined conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). Controls received placebo pills. Although it reduces liver production of lipids, oral estrogen also induces thrombogenic liver proteins. The balance of salutary (lipid-lowering) versus harmful (thrombogenic) effects favors the latter in subjects with endothelial disease, as is found in women who are well past menopause or have disordered vascular endothelium or both<sup><a href="#ref-36">36</a></sup>. In the HERS, the average age of the women who experienced previous cardiovascular events and began administration of estrogen plus MPA was 66.7 years. Therefore, all HERS subjects were at high risk for both VTE and its complications or rapid recurrence of their underlying CVD. Not surprisingly, VTE, stroke, and recurrence of cardiovascular events appeared in the first year of the treatment, which stopped the HERS. Additional issues are mentioned in the following paragraphs.</p><p class="" id=d21666e438>In the WHI trial, the women in the two HT arms received daily oral CEE plus MPA (intact, with natural menopause) or daily oral CEE (premature menopause, post-hysterectomy). Both groups of HT began MHT at an average of about 63 years of age and were more than 10 years post-menopause when starting treatment. When the results were examined without stratification for age, it was found that there was an excess of VTEs in the first year of the trial<i></i> in the women who received treatment<i></i> compared with placebo subjects<sup><a href="#ref-37">37</a></sup>. Since the subjects in the WHI had risk factors for CVD but no demonstrated clinical CVD, the cause of the excess VTEs has undergone considerable thought and investigation. Stratification of the WHI into age groups and re-analysis of the outcomes showed that the cardiovascular complications are limited mainly to women who began MHT after a decade of absent ovarian estrogens<sup><a href="#ref-38">38</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e456>Comparison of the WHI subjects with the usual perimenopausal woman</h2><p class="" id=d21666e459>Since the age and composition of the full WHI cohort made it impossible to evaluate MHT rather than HT<sup><a href="#ref-39">39</a></sup>, it is important to understand how the WHI cohort was constructed. The average age of women in the US at the time of menopause is 51.4 years. Those treated receive MHT for symptoms, mainly hot flushes. In contradistinction, the WHI tested older women and not more than 10% were symptomatic. Since the typical woman begins to decrease her vasomotor symptoms at 5 years and they are usually gone by 7 years past menopause<sup><a href="#ref-40">40</a></sup>, the WHI tested HT and not MHT. The reasons for the inclusion of women of such advanced ages are as follows: (1) Because the effect of estrogen on hot flushes would differentiate between treatment and placebo groups and this could affect adherence to the assigned treatment protocol, moderately symptomatic women were limited to 10% in the WHI; this required inclusion of older, non-symptomatic, post-menopausal women. (2) Since the end points used in the WHI were to be actual cardiovascular events, such as myocardial infarction and intractable angina, and the expected rate of these end points in newly menopausal women during the proposed 7-year length of the study was very low, the power of the WHI to show significant differences between treatment and placebo groups would require prohibitive numbers of study subjects. To satisfy the need to restrict the number of symptomatic subjects and to include subjects with higher risk, it was decided to include women distant from menopause<sup><a href="#ref-40">40</a></sup>. That is, the WHI subjects were as old as 79 years (average of about 63 years) when they started hormones<sup><a href="#ref-36">36</a></sup>. Since most of the subjects were more than 10 years past menopause and were not symptomatic, these women were receiving hormone treatment not resembling MHT for the menopause.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e482>Analysis of the factors leading to excess adverse cardiovascular events in the WHI</h2><p class="" id=d21666e485>After the application of sub-analyses and additional study designs, the WHI has furnished more useful insights into the role of hormones in cardioprotection and age-related CVD. Re-analysis of the WHI subjects for VTE and effects of HT showed that the excess of the main complication, VTE, occurred mainly in the first year of treatment and among the more elderly subjects<sup><a href="#ref-41">41</a></sup>. Thus, sub-clinical CVD with endothelial deterioration may have been betrayed by the induction of thrombogenic liver proteins inherent in the hormonal agents used in the WHI. The younger women in the WHI cohort, having normal vascular endothelium, would not have suffered VTE. A similar situation occurred in the HERS study, in which women with recent CVD events had recurrence in the first year of treatment with hormones<sup><a href="#ref-34">34</a></sup>. Further analysis of the WHI outcomes is available<sup><a href="#ref-42">42</a></sup>. However, the analysis of the effect of the constant dosing regimen of the WHI versus cyclic regimens in other, positive studies has not been reported. Similarly, in none of the recently reported studies has there been a dose-response protocol.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e503>WHI sub-group analyses and imaging studies show that estrogen treatment is cardioprotective</h2><p class="" id=d21666e506>Sub-group analyses of the WHI have explained the discrepancy between the WHI and so many previous studies. The main finding was the breakdown according to age and to estrogen-plus-progestin versus ET. Among subjects who had previously undergone hysterectomy and were 50 to 59 years old at the start of the study, ET women had lower coronary heart disease risk during and following CEE<sup><a href="#ref-43">43</a></sup>. The 50- to 54-year-olds, who were more akin to normal menopausal women who received treatment with MHT, had an even more striking improvement of cardiovascular markers<sup><a href="#ref-43">43</a></sup>. In 2007, Rossouw <i>et al</i>. performed a secondary analysis of the WHI trials, paying attention to age and years since menopause<sup><a href="#ref-44">44</a></sup>. Their results showed a trend toward reduced CVD risk in women who started hormone therapy at a younger age or closer to menopause or both (<a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>)<sup><a href="#ref-44">44</a></sup>. Whereas MHT with ET is clearly effective, MHT with MPA is not. Because MPA is a progestin and reduces expression of estrogen receptors, the difference in outcomes between the two treatments may be ascribed to the progestin<sup><a href="#ref-45">45</a><a href="#ref-47">47</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Cardiovascular and global index events by age at baseline.</h3><p id=d21666e552>Reprinted from Rossouw <i>et al</i>.<sup><a href="#ref-44">44</a></sup> with permission.</p></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21666e563 class=n-a></a><thead><a name=d21666e565 class=n-a></a><tr><a name=d21666e567 class=n-a></a><th colspan=1 rowspan=4><a name=d21666e569 class=n-a></a></th><th align=center colspan=9 rowspan=1 valign=top><a name=d21666e571 class=n-a></a>Age Group at Randomization</th><th align=center colspan=1 rowspan=4 valign=bottom><a name=d21666e574 class=n-a></a><i>P</i> Value for<br class=br>Trend<a href="#TFN2"></a></th></tr><tr><a name=d21666e584 class=n-a></a><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e586 class=n-a></a>5059y</th><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e589 class=n-a></a>6069y</th><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e592 class=n-a></a>7079y</th></tr><tr><a name=d21666e596 class=n-a></a><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e598 class=n-a></a>No. of Cases</th><th colspan=1 rowspan=1><a name=d21666e601 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e603 class=n-a></a>No. of Cases</th><th colspan=1 rowspan=1><a name=d21666e606 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e608 class=n-a></a>No. of Cases</th><th colspan=1 rowspan=1><a name=d21666e612 class=n-a></a></th></tr><tr><a name=d21666e615 class=n-a></a><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e617 class=n-a></a>Hormone<br class=br>Therapy<br class=br>(n=4476)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e624 class=n-a></a>Placebo<br class=br>(n=4356)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e629 class=n-a></a>HR<br class=br>(95% CI)<a href="#TFN1">*</a></th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e636 class=n-a></a>Hormone<br class=br>Therapy<br class=br>(n=6240)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e643 class=n-a></a>Placebo<br class=br>(n=6122)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e649 class=n-a></a>HR<br class=br>(95% CI)<a href="#TFN1">*</a></th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e656 class=n-a></a>Hormone<br class=br>Therapy<br class=br>(n=3100)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e663 class=n-a></a>Placebo<br class=br>(n=3053)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d21666e668 class=n-a></a>HR<br class=br>(95% CI)<a href="#TFN1">*</a></th></tr></thead><tbody><a name=d21666e677 class=n-a></a><tr><a name=d21666e679 class=n-a></a><td align=center colspan=11 rowspan=1 valign=top><a name=d21666e681 class=n-a></a><b>Combined Trials</b></td></tr><tr><a name=d21666e686 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e688 class=n-a></a>CHD<a href="#TFN3"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e693 class=n-a></a>59</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e696 class=n-a></a>61</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e699 class=n-a></a>0.93<br class=br>(0.65-1.33)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e704 class=n-a></a>174</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e708 class=n-a></a>178</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e711 class=n-a></a>0.98<br class=br>(0.79-1.21)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e716 class=n-a></a>163</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e719 class=n-a></a>131</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e722 class=n-a></a>1.26<br class=br>(1.00-1.59)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e727 class=n-a></a>.16</td></tr><tr><a name=d21666e731 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e733 class=n-a></a>Stroke</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e736 class=n-a></a>44</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e739 class=n-a></a>37</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e742 class=n-a></a>1.13<br class=br>(0.73-1.76)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e747 class=n-a></a>156</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e751 class=n-a></a>102</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e754 class=n-a></a>1.50<br class=br>(1.17-1.92)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e759 class=n-a></a>127</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e762 class=n-a></a>100</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e765 class=n-a></a>1.21<br class=br>(0.93-1.58)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e770 class=n-a></a>.97</td></tr><tr><a name=d21666e774 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e776 class=n-a></a>Total<br class=br>mortality</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e781 class=n-a></a>69</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e784 class=n-a></a>95</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e787 class=n-a></a>0.70<br class=br>(0.51-0.96)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e792 class=n-a></a>240</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e796 class=n-a></a>225</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e799 class=n-a></a>1.05<br class=br>(0.87-1.26)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e804 class=n-a></a>237</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e807 class=n-a></a>208</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e810 class=n-a></a>1.14<br class=br>(0.94-1.58)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e815 class=n-a></a>.06</td></tr><tr><a name=d21666e819 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e821 class=n-a></a>Global<br class=br>index<a href="#TFN4"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e828 class=n-a></a>278</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e831 class=n-a></a>278</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e834 class=n-a></a>0.96<br class=br>(0.81-1.14)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e839 class=n-a></a>717</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e843 class=n-a></a>661</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e846 class=n-a></a>1.08<br class=br>(0.97-1.20)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e851 class=n-a></a>606</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e854 class=n-a></a>528</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e857 class=n-a></a>1.14<br class=br>(1.02-1.29)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e862 class=n-a></a>.09</td></tr><tr><a name=d21666e867 class=n-a></a><td align=center colspan=11 rowspan=1 valign=top><a name=d21666e869 class=n-a></a><b>CEE Trial</b></td></tr><tr><a name=d21666e874 class=n-a></a><td colspan=1 rowspan=1><a name=d21666e876 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e878 class=n-a></a><b>CEE</b><br class=br><b>(n=1637)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e885 class=n-a></a><b>Placebo</b><br class=br><b>(n=1673)</b></td><td colspan=1 rowspan=1><a name=d21666e892 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e894 class=n-a></a><b>CEE</b><br class=br><b>(n=2387)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e902 class=n-a></a><b>Placebo</b><br class=br><b>(n=2465)</b></td><td colspan=1 rowspan=1><a name=d21666e909 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e911 class=n-a></a><b>CEE</b><br class=br><b>(n=1286)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e918 class=n-a></a><b>Placebo</b><br class=br><b>(n=1291)</b></td><td colspan=1 rowspan=1><a name=d21666e925 class=n-a></a></td><td colspan=1 rowspan=1><a name=d21666e927 class=n-a></a></td></tr><tr><a name=d21666e930 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e932 class=n-a></a>CHD<a href="#TFN3"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e937 class=n-a></a>21</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e940 class=n-a></a>34</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e943 class=n-a></a>0.63<br class=br>(0.36-1.09)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e948 class=n-a></a>96</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e952 class=n-a></a>106</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e955 class=n-a></a>0.94<br class=br>(0.71-1.24)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e960 class=n-a></a>84</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e963 class=n-a></a>77</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e966 class=n-a></a>1.13<br class=br>(0.82-1.54)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e971 class=n-a></a>.12</td></tr><tr><a name=d21666e975 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e977 class=n-a></a>Stroke</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e980 class=n-a></a>18</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e983 class=n-a></a>21</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e986 class=n-a></a>0.89<br class=br>(0.47-1.69)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e991 class=n-a></a>84</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e995 class=n-a></a>54</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e998 class=n-a></a>1.62<br class=br>(1.15-2.27)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1003 class=n-a></a>66</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1006 class=n-a></a>52</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1009 class=n-a></a>1.21<br class=br>(0.84-1.75)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1014 class=n-a></a>.62</td></tr><tr><a name=d21666e1018 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1020 class=n-a></a>Total<br class=br>mortality</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1025 class=n-a></a>34</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1028 class=n-a></a>48</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1031 class=n-a></a>0.71<br class=br>(0.46-1.11)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1036 class=n-a></a>129</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1040 class=n-a></a>131</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1043 class=n-a></a>1.02<br class=br>(0.80-1.30)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1048 class=n-a></a>134</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1051 class=n-a></a>113</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1054 class=n-a></a>1.20<br class=br>(0.93-1.55)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1059 class=n-a></a>.18</td></tr><tr><a name=d21666e1063 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1065 class=n-a></a>Global<br class=br>index<a href="#TFN4"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1072 class=n-a></a>114</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1075 class=n-a></a>140</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1078 class=n-a></a>0.82<br class=br>(0.64-1.05)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1083 class=n-a></a>333</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1087 class=n-a></a>342</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1090 class=n-a></a>1.01<br class=br>(0.86-1.17)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1095 class=n-a></a>300</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1098 class=n-a></a>262</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1101 class=n-a></a>1.16<br class=br>(0.98-1.37)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1106 class=n-a></a>.01</td></tr><tr><a name=d21666e1111 class=n-a></a><td align=center colspan=11 rowspan=1 valign=top><a name=d21666e1113 class=n-a></a><b>CEE + MPA Trial</b></td></tr><tr><a name=d21666e1118 class=n-a></a><td colspan=1 rowspan=1><a name=d21666e1120 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1122 class=n-a></a><b>CEE + MPA</b><br class=br><b>(n=2839)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1129 class=n-a></a><b>Placebo</b><br class=br><b>(n=2683)</b></td><td colspan=1 rowspan=1><a name=d21666e1136 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1138 class=n-a></a><b>CEE + MPA</b><br class=br><b>(n=3853)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1146 class=n-a></a><b>Placebo</b><br class=br><b>(n=3657)</b></td><td colspan=1 rowspan=1><a name=d21666e1153 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1155 class=n-a></a><b>CEE + MPA</b><br class=br><b>(n=1814)</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1162 class=n-a></a><b>Placebo</b><br class=br><b>(n=1762)</b></td><td colspan=1 rowspan=1><a name=d21666e1169 class=n-a></a></td><td colspan=1 rowspan=1><a name=d21666e1171 class=n-a></a></td></tr><tr><a name=d21666e1174 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1176 class=n-a></a>CHD<a href="#TFN3"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1181 class=n-a></a>38</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1184 class=n-a></a>27</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1187 class=n-a></a>1.29<br class=br>(0.79-2.12)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1192 class=n-a></a>78</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1196 class=n-a></a>72</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1199 class=n-a></a>1.03<br class=br>(0.74-1.43)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1204 class=n-a></a>79</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1207 class=n-a></a>54</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1210 class=n-a></a>1.48<br class=br>(1.04-2.11)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1215 class=n-a></a>.70</td></tr><tr><a name=d21666e1219 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1221 class=n-a></a>Stroke</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1224 class=n-a></a>26</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1227 class=n-a></a>16</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1230 class=n-a></a>1.41<br class=br>(0.75-2.65)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1235 class=n-a></a>72</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1239 class=n-a></a>48</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1242 class=n-a></a>1.37<br class=br>(0.95-1.97)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1247 class=n-a></a>61</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1250 class=n-a></a>48</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1253 class=n-a></a>1.21<br class=br>(0.82-1.78)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1258 class=n-a></a>.56</td></tr><tr><a name=d21666e1262 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1264 class=n-a></a>Total<br class=br>mortality</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1269 class=n-a></a>35</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1272 class=n-a></a>47</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1275 class=n-a></a>0.69<br class=br>(0.44-1.07)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1280 class=n-a></a>111</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1284 class=n-a></a>94</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1287 class=n-a></a>1.09<br class=br>(0.83-1.44)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1292 class=n-a></a>103</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1295 class=n-a></a>95</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1298 class=n-a></a>1.06<br class=br>(0.80-1.41)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1303 class=n-a></a>.19</td></tr><tr><a name=d21666e1307 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1309 class=n-a></a>Global<br class=br>index<a href="#TFN4"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1316 class=n-a></a>164</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1319 class=n-a></a>138</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1322 class=n-a></a>1.10<br class=br>(0.87-1.38)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1327 class=n-a></a>384</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1331 class=n-a></a>319</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1334 class=n-a></a>1.15<br class=br>(0.99-1.34)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1339 class=n-a></a>306</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1342 class=n-a></a>266</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1345 class=n-a></a>1.13<br class=br>(0.95-1.33)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1350 class=n-a></a>.96</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21666e1358 class=n-a></a><p id=d21666e1360> Abbreviations: CEE, conjugated equine estrogens; CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MPA, medroxyprogesterone acetate.</p><p id=TFN1>*Cox regression models stratified according to prior cardiovascular disease and randornization status in the Dietary modification Trial.</p><p id=TFN2>Test for trend (interaction) using age as continuous (linear) form of categorical coded values. Cox regression models stratified according to active vs placebo and trial, including terms for age and the interaction between trials and age.</p><p id=TFN3>Defined as CHD death, nonfatal myocardial infarcation, or definite silent myocardial infarction (Novacode 5.1 or 5.2).</p><p id=TFN4>Defined as CHD, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer for CEE plus MPA trial only, hip fracture, or death from other causes.</p></div></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Estimated absolute excess risk per 10,000 person-years by age group at baseline.</h3><p id=d21666e1388>Reprinted from Rossouw <i>et al</i>.<sup><a href="#ref-44">44</a></sup> with permission.</p></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d21666e1399 class=n-a></a><thead><a name=d21666e1401 class=n-a></a><tr><a name=d21666e1403 class=n-a></a><th colspan=1 rowspan=3><a name=d21666e1405 class=n-a></a></th><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e1407 class=n-a></a>Combined Trials</th><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e1410 class=n-a></a>CEE Trial</th><th align=center colspan=3 rowspan=1 valign=top><a name=d21666e1413 class=n-a></a>CEE + MPA Trial</th></tr><tr><a name=d21666e1417 class=n-a></a><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e1419 class=n-a></a>Cases per<br class=br>100 Person-Years</th><th colspan=1 rowspan=2><a name=d21666e1424 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e1426 class=n-a></a>Cases per<br class=br>100 Person-Years</th><th colspan=1 rowspan=2><a name=d21666e1431 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d21666e1433 class=n-a></a>Cases per<br class=br>100 Person-Years</th><th colspan=1 rowspan=2><a name=d21666e1439 class=n-a></a></th></tr><tr><a name=d21666e1442 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1444 class=n-a></a>Hormone<br class=br>therapy</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1449 class=n-a></a>Placebo</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1452 class=n-a></a>CEE</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1455 class=n-a></a>Placebo</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1458 class=n-a></a>CEE+MPA</th><th align=center colspan=1 rowspan=1 valign=top><a name=d21666e1462 class=n-a></a>Placebo</th></tr></thead><tbody><a name=d21666e1467 class=n-a></a><tr><a name=d21666e1469 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1471 class=n-a></a>CHD<br class=br>&nbsp;&nbsp;Age Group, y<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;5059<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;6069<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;7079</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1482 class=n-a></a><br class=br><br class=br>0.20<br class=br>0.46<br class=br>0.90</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1491 class=n-a></a><br class=br><br class=br>0.22<br class=br>0.48<br class=br>0.72</td><td colspan=1 rowspan=5><a name=d21666e1500 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T1.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_T1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T1.gif"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1503 class=n-a></a><br class=br><br class=br>0.17<br class=br>0.58<br class=br>0.98</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1513 class=n-a></a><br class=br><br class=br>0.27<br class=br>0.62<br class=br>0.88</td><td colspan=1 rowspan=5><a name=d21666e1522 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T2.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_T2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T2.gif"></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1525 class=n-a></a><br class=br><br class=br>0.22<br class=br>0.36<br class=br>0.82</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1534 class=n-a></a><br class=br><br class=br>0.17<br class=br>0.36<br class=br>0.58</td><td colspan=1 rowspan=5><a name=d21666e1543 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T3.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_T3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_T3.gif"></a></td></tr><tr><a name=d21666e1547 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1549 class=n-a></a>Storke<br class=br>&nbsp;&nbsp;Age Group, y<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;5059<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;6069<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;7079</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1560 class=n-a></a><br class=br><br class=br>0.15<br class=br>0.41<br class=br>0.70</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1569 class=n-a></a><br class=br><br class=br>0.13<br class=br>0.27<br class=br>0.55</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1578 class=n-a></a><br class=br><br class=br>0.15<br class=br>0.51<br class=br>0.76</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1587 class=n-a></a><br class=br><br class=br>0.17<br class=br>0.31<br class=br>0.59</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1597 class=n-a></a><br class=br><br class=br>0.15<br class=br>0.34<br class=br>0.63</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1606 class=n-a></a><br class=br><br class=br>0.10<br class=br>0.24<br class=br>0.52</td></tr><tr><a name=d21666e1616 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1618 class=n-a></a>Total Mortality<br class=br>&nbsp;&nbsp;Age Group, y<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;5059<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;6069<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;7079</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1629 class=n-a></a><br class=br><br class=br>0.24<br class=br>0.46<br class=br>1.28</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1638 class=n-a></a><br class=br><br class=br>0.34<br class=br>0.60<br class=br>1.14</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1647 class=n-a></a><br class=br><br class=br>0.28<br class=br>0.77<br class=br>1.53</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1656 class=n-a></a><br class=br><br class=br>0.38<br class=br>0.75<br class=br>1.27</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1666 class=n-a></a><br class=br><br class=br>0.21<br class=br>0.51<br class=br>1.06</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1675 class=n-a></a><br class=br><br class=br>0.30<br class=br>0.47<br class=br>1.01</td></tr><tr><a name=d21666e1685 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d21666e1687 class=n-a></a>Global Index<br class=br>&nbsp;&nbsp;Age Group, y<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;5059<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;6069<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;7079</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1698 class=n-a></a><br class=br><br class=br>0.97<br class=br>1.95<br class=br>3.50</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1707 class=n-a></a><br class=br><br class=br>1.01<br class=br>1.83<br class=br>3.06</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1716 class=n-a></a><br class=br><br class=br>0.95<br class=br>2.07<br class=br>3.67</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1725 class=n-a></a><br class=br><br class=br>1.15<br class=br>2.07<br class=br>3.13</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1735 class=n-a></a><br class=br><br class=br>0.99<br class=br>1.85<br class=br>3.35</td><td align=center colspan=1 rowspan=1 valign=top><a name=d21666e1744 class=n-a></a><br class=br><br class=br>0.89<br class=br>1.64<br class=br>2.99</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d21666e1758 class=n-a></a><p id=d21666e1760> The estimated absolute excess risk may differ slightly from the absolute excess risk derived from the differences in cases pler 100 person-years betwee active hormone and placebo groups. Estimated absolute exvess risk was per 10 000 person-years calculated as [annualized percentage in the placebo in the palcebo group  (hazard tatio in the placbo group 1)]  1000. Error bars indicate 95% confidence intervals, estimated using bootstrap methods. CEE indicates conjugated equine estrogens; CHD, coronary heart disease; MPA, medroxyprogesterone acetate.</p><p id=d21666e1763>*<i>P</i>=.03 compared with the age group of 50 to 59 years.</p><p id=d21666e1769><i>P</i>=.02 compared with the age group of 50 to 59 years.</p><p id=d21666e1775><i>P</i>=.01 compared with the age group of 50 to 59 years.</p></div></div></div><p class="" id=d21666e1784>Although most of the information regarding the possible adverse effects of medroxyprogesterone compared with progesterone deals with breast cancer, there are other aspects that may affect the cardioprotective effect of estrogen<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>. For example, in the WHI Coronary Artery Calcification Study (WHI-CACS), which lasted a mean of 7.4 years, women in the 50 to 59 age group who received estrogen had lower mean CAC scores than women in the same age group who were given placebo (83.1 versus 123.1, <i>P</i> = 0.02). The lack of a protective effect of added MPA is evidence of the cardioprotective effect of estrogen when initiated close to the time of menopause and used without progestogen<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d21666e1802>The most recent evaluation of the WHI results shows that in women in the 50 to 54 age group, who had undergone premature menopause and were treated with ET, all categories of measurement of CVD and of cardiovascular events demonstrated an excess in the placebo group compared with the ET subjects.Unfortunately, for most of the categories, there was insufficient numerical power to prove statistical significance<sup><a href="#ref-23">23</a></sup>. A similar result was found by comparing the WHI sub-groups with the observational NHS<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d21666e1813>In two studies of CAC, after prolonged use of hormone replacement therapy, less CAC was found in the users than in never-users<sup><a href="#ref-32">32</a>,<a href="#ref-51">51</a></sup>.</p><p class="" id=d21666e1823>The final measure of cardioprotection is evidence of differences in cardiovascular death rates from MHT versus no treatment or placebo. At present, the WHI combined follow-up studies are at 18 years. Although they show a slight lowering in the average number of cardiovascular deaths in timely (starting at 50 to 59 years of age) MHT-treated women, the total number of deaths in that group is too low (18) to furnish statistical significance<sup><a href="#ref-52">52</a></sup>. Moreover, the evaluations are bound by the type of regimen used, which is a serious stricture<sup><a href="#ref-42">42</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e1837>The timing hypothesis of estrogen cardioprotection may explain the failure of late-start MHT/HT to protect against development of clinical atherosclerosis in the WHI</h2><p class="" id=d21666e1840>The timing hypothesis of estrogen-induced cardioprotection first proposed by Thomas Clarkson in 1998 appears to explain the failure of the WHI to show a protective effect of MHT/HT in any but its 50- to 59-year-old subjects. Based on his studies of female cynomolgus monkeys, Clarkson proposed that since atherosclerotic vascular plaque is irreversible by MHT, the beneficial effects of MHT are dependent on initiation before plaque has formed. That the development of plaque is also a product of risk factors was evidenced by his use of a high-lipid diet as the atherogenic stimulus during experiments inducing plaque versus reducing plaque with CEE<sup><a href="#ref-50">50</a></sup>. For the sake of brevity, the normal course of plaque development is shown in <a href="#f2">Figure 2</a><sup><a href="#ref-53">53</a></sup>. Monocytes are captured by inflamed vascular endothelial cells in part via tethers of nCAM:nCAM molecules expressed by monocytes and endothelial cells<sup><a href="#ref-20">20</a></sup>. Coronary vessel endothelial cells express aromatase and estrogen receptors<sup><a href="#ref-13">13</a></sup>. Estrogen prevents atherogenesis by inducing sialylases that sialylate (sugar-coat) nCAM molecules extracellular domains, thereby blocking the nCAM:nCAM tethers<sup><a href="#ref-13">13</a></sup>. Clarkson mimicked these stages by removing the ovaries in female monkeys and then using CEE plus medroxyprogesterone treatment to block plaque formation during feeding with an atherogenic diet. Clarkson found that, once established, estrogen does not remove plaque; when he treated monkeys with CEE after the plaque was established, there was no regression of plaque. He then proposed the timing hypothesis: early ET prevents plaque formation in normal post-menopausal subjects but late treatment does not and therefore the latter is not cardioprotective<sup><a href="#ref-54">54</a></sup>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure2.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure2.gif"></a><div class=caption><h3>Figure 2. Schematic representation of the natural history of coronary atherosclerosis in American women.</h3><p id=d21666e1880>ET/HT, estrogen treatment/hormone treatment. Reprinted from Mikkola <i>et al</i>.<sup><a href="#ref-53">53</a></sup> with permission.</p></div></div><p class="" id=d21666e1894>Many authors have voiced support for the timing hypothesis as an explanation for the failure of the initial interpretation of the WHI cohort to show cardioprotection by ET, and they raised the question of whether the overall rate of VTE in the WHI was related to the presence of sub-clinical atherosclerosis and increased clotting propensity<sup><a href="#ref-55">55</a><a href="#ref-57">57</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e1907>Confirmation of the timing hypothesis in humans</h2><p class="" id=d21666e1910>The monkey atheroprotection timing hypothesis was verified in a prospective randomized clinical trial performed explicitly for that purpose. In March 2016, the ELITE Research Group published the first randomized control trial to test the timing hypothesis<sup><a href="#ref-58">58</a></sup>. They divided 643 healthy post-menopausal women according to the time since menopause (&lt;6 years or 10 years) and randomly assigned them to receive either oral estradiol plus vaginal progesterone or placebo. Their primary outcome was the rate of change in CIMT. They found that, in the early post-menopausal cohort, the rate of CIMT progression was significantly lower in the estradiol group than in the placebo group; this effect was not seen in the late post-menopausal cohort (<a href="#f3">Figure 3</a>). Comparable data gleaned from the Peking study<sup><a href="#ref-32">32</a></sup> and the WHI support the findings of the ELITE study<sup><a href="#ref-58">58</a></sup>.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure3.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure3.gif"></a><div class=caption><h3>Figure 3. Carotid intima-media thickness (CIMT) progression according to post-menopausal years at the start of treatment.</h3><p id=d21666e1938>The strata are early (up to 6 years before menopausal hormone treatment, or MHT) and late (&gt;6 years before MHT). Reprinted from Hodis <i>et al</i>.<sup><a href="#ref-58">58</a></sup> with permission.</p></div></div><p class="" id=d21666e1952>Taken together, the multitude of epidemiological, retrospective, and prospective studies support a protective role for properly timed MHT/ET against CVD. Sub-analysis of the WHI plus its ancillary studies strongly supports the cardioprotective effect of ET in menopausal women<sup><a href="#ref-44">44</a></sup>. The active agent appears to be the estrogen since the addition of progestin reduces the protective effect. However, it must remain clear that, thus far, only indicators of cardioprotection have been adduced. A prospective study is needed to clarify whether properly timed MHT/ET prevents or delays actual cardiac events such as myocardial infarction, heart failure, or death.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e1962>When to begin menopausal hormone treatment</h2><p class="" id=d21666e1965>It is now indisputable that the prevention of CVD depends on the timing of initiation of MHT. <i>Unless there is a clear contraindication, premature menopause patients (surgical or otherwise) should start treatment at the first opportunity.</i></p><p class="" id=d21666e1970>In regard to natural menopause, most governing bodies have recommended the initiation of MHT within the first 10 years of menopause or at the onset of menopausal symptoms<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. Hodis <i>et al</i>.<sup><a href="#ref-58">58</a></sup> focus on the menopausal age over the chronological age. We agree that, when possible, MHT should be initiated as close as possible to menopause or at the onset of menopausal symptoms. Given currently available data comparing the risk of VTE with the cardiovascular benefits of slowing CIMT, 6 years is an appropriate soft cutoff for starting MHT in women without high-risk factors for CVD. In the presence of risk factors (hypertension, elevated lipids, and metabolic syndrome), a work-up for clotting factors and sub-clinical CVD is appropriate before starting long-term MHT for any reason. Initiating MHT during this optimal window also allows the opportunity to improve menopausal symptoms, prevent osteoporosis, and treat the metabolic syndrome and its complications<sup><a href="#ref-31">31</a></sup>.</p><p class="" id=d21666e1991>Pre-menopausal treatment with MHT is inappropriate because of the large and unpredictable swings of hormones during that period; the most efficient treatments of bleeding and symptoms in properly screened pre-menopausal women are oral contraceptives<sup><a href="#ref-61">61</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2001>In summary</h2><p class="" id=d21666e2004>Preclinical and clinical studies support the cardioprotective value of timely (that is, within 5 to 10 years of menopause) application of MHT. This rule appears to hold regardless of the severity of menopausal symptoms. The risk of VTE is related to age and is not a contraindication in properly screened, early menopausal women.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2011>What treatment to use</h2><p class="" id=d21666e2014>This question itself requires its own review and cannot be further addressed here. The data presented in this article address the outcomes of type 1 trials (randomized, blinded, placebo-controlled), except as noted. There are many other treatment regimens that either are not relevant to the specific question of cardiovascular health or were not included because of the paucity of type 1 trial data. To peruse this important subject, we suggest that the reader begin with the current American College of Obstetricians and Gynecologists Practice Bulletin<sup><a href="#ref-59">59</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2024>When to halt treatment</h2><p class="" id=d21666e2027>One of the most important lessons to be learned, or re-learned, from the extended evaluation and observational studies of the WHI is confirmation of the positive effects of ET/MHT on symptoms, bone health, metabolic syndrome, and cardiovascular health. This is especially true regarding long-term outcomes<sup><a href="#ref-33">33</a>,<a href="#ref-35">35</a>,<a href="#ref-41">41</a>,<a href="#ref-42">42</a></sup>. The follow-up WHI studies regarding cardiovascular events, especially deaths from myocardial infarction or post-infarctional heart failure, are currently reaching sufficient cases to confirm the cardioprotective effects of MHT/ET, but there is no scientifically gathered information about when to halt treatment. There are no prospective data regarding shortening the safe length of treatment or prevention of menopausal complications. On the contrary, there is much data indicating that women can safely receive MHT for extended periods<sup><a href="#ref-7">7</a>,<a href="#ref-32">32</a></sup>.</p><p class="" id=d21666e2050>The US Food and Drug Administration recommends that hormones should be used at the lowest dose for the shortest duration consistent with therapeutic goals<sup><a href="#ref-62">62</a></sup>, generally taken to mean approximately 5 years maximum. But observational studies evaluating MHT duration suggest that the protective effects of MHT against coronary heart disease may become apparent only after many years of treatment<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. In a re-evaluation of the WHI estrogen-plus-progestin arm, Toh <i>et al</i>.<sup><a href="#ref-65">65</a></sup> found that women starting MHT within 10 years after menopause had a CVD hazard ratio over the first 2 years of treatment of 1.29 (CI 0.523.18) but that after 8 years of treatment this decreased to 0.64 (CI 0.211.99). Harman <i>et al</i>.<sup><a href="#ref-66">66</a></sup> evaluated published results of the WHI ET trial and found that coronary heart disease incidence rates were similar between placebo and ET patients in years 1 through 6. However, with more than 6 years of ET, there was a statistically significant decrease in CVD risk as compared with the placebo group (<a href="#f4">Figure 4</a>). There is ample evidence that closely supervised women taking MHT can safely continue for decades.</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure4.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure4.gif"></a><div class=caption><h3>Figure 4. Annual incidence of coronary heart disease events per 10,000 women in the Womens Health Initiative Estrogen Alone trial.</h3><p id=d21666e2092>CEE, conjugated equine estrogen; CHD, coronary heart disease. Reprinted from Harman <i>et al</i>.<sup><a href="#ref-66">66</a></sup> with permission.</p></div></div><p class="" id=d21666e2106>The Kronos Early Estrogen Prevention Study (KEEPS) low-dose MHT trial, though showing improvement of risk factors for CVD, failed to show a slowing of the increase of CIMT by 4 years of estradiol-plus-progesterone treatment. This may have been due to the inability of CIMT measurements to reveal cardioprotection that occurred during the 4 years of the trial<sup><a href="#ref-67">67</a></sup> since the ELITE study confirmed that even normal CIMT women have increases in their CIMT after menopause. Under the ELITE hormonal regimen, improved CIMT over placebo treatment was not apparent until 3 or 4 years of treatment and did not reach statistical significance until 5 years of treatment<sup><a href="#ref-58">58</a></sup> (<a href="#f3">Figure 3</a>). We believe that the reason for the lack of similar findings in the KEEPS was the exclusion of test subjects who had evidence of sub-clinical CVD (CAC of  50 Agatston units) at the time of registration<sup><a href="#ref-67">67</a></sup>.</p><p class="" id=d21666e2125>At this point, there are no published prospective studies regarding the limits of estrogen-induced cardioprotection in women starting MHT within 10 years of menopause. However, continued bone protection and metabolic protection have been documented<sup><a href="#ref-68">68</a></sup>.</p><p class="" id=d21666e2132>With increasing age, issues regarding cognition and general brain deterioration arise. This may proceed to dementia. At present, there is no clinical testing that satisfactorily determines the type of dementia: vascular dementia (VD) or degenerative dementia (Alzheimers disease, or AD). In general, both diseases are present in all patients with dementia but the relative impact of each is not known, nor is the effect of age versus other causes, such as estrogen deficiency. Many studies have shown that estrogen may be preventive against aspects of AD and VD. At present, since amyloid deposition is found in brain vessels and nervous system plaques, we must be very guarded about the possible effects of hormones in preventing or treating specific forms of dementia<sup><a href="#ref-69">69</a></sup>. Although protection against dementia has been inferred from retrospective studies, the recent mortality rates from the 18-year follow-up of the WHI indicated a reduced occurrence at autopsy of both dementia and AD in the CEE group<sup><a href="#ref-52">52</a></sup>. One retrospective report of women who used low dosing regimens for up to 31 years showed no difference in VTE or other adverse events, but the CIMTs and CACs were significantly lower in the patients who received treatment versus controls<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d21666e2147>The effect of age versus MHT on brain VTE remains an unresolved issue. Systemic VTE is a rare and symptomatic occurrence during the first decade after menopause. Brain vessel VTE rates and timing are only known when associated with symptoms, yet the brain, especially the white matter, shrinks with aging. This is under study<sup><a href="#ref-70">70</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2157>In summary</h2><p class="" id=d21666e2160>Simply stopping MHT/ET at some arbitrary time seems premature. The length of treatment should be based on health surveillance. This means that MHT administration must be accompanied by regular, periodic examinations, including pelvic exams, cervical cancer testing (especially when there is a change in partners without knowledge of human papillomavirus status), and mammograms. These visits should include discussions with the patient regarding the effects of continuing or halting treatment. For example, MHT protection against the metabolic syndrome and its inflammatory effects is well established, as is protection against bone loss and fracture. Although ET is clearly protective against invasive breast cancer, the jury is still out on ovarian cancer<sup><a href="#ref-71">71</a></sup> and both are often found in post-menopausal women regardless of their history of MHT. The overlap may complicate the discussion but is itself not a reason for halting MHT/ET.</p><p class="" id=d21666e2167>In the case of estrogen and cardioprotection, although trials of more than 5 years have shown the protective effects of MHT (specifically estrogen) up to 11 years and case control studies show protection into the fourth decade of use, there are no trials addressing the acceptable length of treatment. However, women with (predominantly surgical) premature menopause commonly continue estrogen until death, usually decades later and from a variety of causes<sup><a href="#ref-7">7</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2177>A holistic template for prevention and treatment which may afford cardioprotection for post-menopausal women</h2><p class="" id=d21666e2180>No woman comes to menopause without the imprint of her genome, intervening events since birth, and environmental/lifestyle effects. This often results in sub-clinical disease prior to the milestone of menopause. If the progress of these ailments is clinically evident, women with sub-clinical CVD may already be receiving care when they cease ovarian estrogen secretion. However, their sub-clinical CVD often will not have been diagnosed or treated. In such cases, the onset of menopausal symptoms can be a defining moment since this brings the woman to the attention of health-care professionals. At that moment, the patient is open to consideration and even acceptance of changes in lifestyle and other aspects of prevention/disease management. Although this is opportune, it is often too late to forestall sub-clinical disease. <a href="#f5">Figure 5</a> diagrams the chronological relationship of disease development (including CVD in high-risk women), the chronological age, and reproductive stage. The presence of sub-clinical CVD and endothelial dysfunction predisposes the patient who receives MHT to VTE (see above) and should be carefully evaluated before suggesting ET/MHT. It may be useful to evaluate CIMT and CAC or to perform tests of endothelial dysfunction prior to starting ET/MHT. This is especially true for women who are more than 5 years post-menopause (that is, 6 years since their last menstrual period)<sup><a href="#ref-58">58</a></sup>.</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure5.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure5.gif"></a><div class=caption><h3>Figure 5. A diagram of the relationship of chronological age and reproductive stage to the development of chronic diseases in women who are vulnerable because of risk factors and lifestyle.</h3><p id=d21666e2200>Space constraints limit the diseases that may begin or manifest with age. Not all women will undergo these conditions, nor do they all manifest precisely in the periods bracketed.</p></div></div><p class="" id=d21666e2207>The above descriptions of the genesis of atherosclerosis and the background of the timing hypothesis indicate that starting prevention or treatment of CVD should not await menopause. With this in mind, a program of early education, risk assessment, healthy interventions, and treatment of nascent or sub-clinical disease may be applied. This is a form of preventive medicine that is familiar to primary care practitioners. It does not require high-tech or extreme measures. The largest impediment to employing these measures is the lack of the patients openness to evaluation and to lifestyle management. However, life events such as pregnancy, illnesses, and menopause often will open womens minds to education and prevention. Practitioners should be aware of the significance of these openings and institute appropriate discussions and measures. <a href="#f6">Figure 6</a> diagrams in broad strokes the usual periods when risk evaluation, education, and preventative measures may be successfully introduced. These are the times of inflection points in womens lives, when they are open to reconsideration of lifestyle changes and so on. Regardless of the diagnostic and treatment plan, the key is to thoroughly discuss it with the patient and to in-build periodic (annual) history-taking and diagnostic measures. It goes without saying that the annual visit will also furnish the benefits of timely diagnosis of non-hormone-related disease.</p><a name=f6 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure6.gif"><img alt="145bf153-a021-41e2-997e-e17f790a656d_figure6.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16960/145bf153-a021-41e2-997e-e17f790a656d_figure6.gif"></a><div class=caption><h3>Figure 6. Insertion of the periods in which education, risk assessment, and various interventions, including menopausal hormone treatment (MHT), may be effectively practiced in the aging woman.</h3><p id=d21666e2223>Annotated version of <a href="#f5">Figure 5</a> with additions in red indicating the periods in which education, risk assessment and various interventions, including MHT, may be effectively be practiced in the aging woman. The vertical dotted line approximates the last age of normal women thus far studied for long-term treatment outcomes (see text). The use of treatment into the post-menopause/geriatric period must be accompanied by annual evaluation. Because of the appearance of sub-clinical and clinical disease in the later years, best Practice indicates that this annual visit should not be discontinued after hormone treatment is stopped.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2236>Summary</h2><p class="" id=d21666e2239>In proven menopausal-normal women, timely initiation of MHT for symptoms is safe compared to the menopausal complications that it treats or prevents. Thus far, evidence indicates that MPA is to be avoided because of its possible link to breast cancer<sup><a href="#ref-47">47</a></sup>. Although a head to head trial has not been published, our choice is to use MHT cyclically rather than continuously. The evidence adduced thus far supports the cardioprotective effects of MHT. Estrogen alone (or treatment that avoids progestin) is especially convincing. But, the final confirmation awaits proof regarding prevention of actual cardiac events. Since MHT is usually administered for menopausal symptoms and vaginal atrophy/sexual dysfunction, but also deterioration of skin turgor or bone health and cardioprotective effects of ET-MHT, given that the latter are not FDA approved indications for MHT, the decision about whether to start or stop MHT is often made in the absence of clinical research results.</p><p class="" id=d21666e2246>The work-up for treatment of menopausal symptoms in women with CVD risk factors should include CIMT or CAC. An age- and sex-adjusted CIMT measurement may not be necessary for evaluation<sup><a href="#ref-72">72</a></sup>. Coronary calcium score is readily available and correlates well with coronary disease. MHT should be combined with lifestyle modification and anti-atherosclerosis medications and regimens. All patients receiving MHT/ET should have annual visits with CVD evaluation.</p><p class="" id=d21666e2253>The decision to continue or stop treatment should be shared between the health-care provider and patient. For most women, the benefits of hormone therapy, including cardioprotection will outweigh the risk. At present, there are no studies indicating a time limit on the administration of properly monitored MHT/ET.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d21666e2259>More research is needed</h2><p class="" id=d21666e2262>Unfortunately, the impact of the original report of the WHI caused a massive decline in the use of MHT<sup><a href="#ref-73">73</a></sup>. This has resulted in a generally decreased interest in the treatment of menopausal women by all sectors of health care. This includes the pharmaceutical industry, which formerly sponsored many of the clinical trials on MHT. But even had the turning away from the regimens tested been warranted, the problem of management of this important and growing group has not lessened. Rather, it continues to increase as the population ages. Without continuing efforts at improving the drug regimens and removing harmful agents and practices from menopausal health care, it is inevitable that there will be increased aggregate misery, cost, and societal impact of age-related ovarian failure. The findings discussed above should be a call to action to further the search for effective lifestyle regimens, educational programs, diagnostic methods, and hormonal and non-hormonal agents with which to confront not only the increased rate of CVD in the post-menopausal years. There is much more research that can be done to properly innovate and test on behalf of these women.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d21666e1 class=n-a></a><h2 class=main-title id=d21932>Author contributions</h2><p class=metadata-entry><a name=d21666e119 class=n-a></a><p id=d21666e120> FN and JF contributed equally to the manuscript. All authors contributed directly to the development and content of the manuscript.</p></p></div><div class=back-section><a name=d21666e2273 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d22167>References</h2><div class="section ref-list"><a name=d21666e2273 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d21666e2280 class=n-a></a>Stuenkel CA, Davis SR, Gompel A, <i> et al.</i>: Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(11): 39754011. <a target=xrefwindow id=d21666e2291 href="http://www.ncbi.nlm.nih.gov/pubmed/26444994">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2294 href="https://doi.org/10.1210/jc.2015-2236">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727753897"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2303 class=n-a></a>The NAMS 2017 Hormone Therapy Position Statement Advisory Panel: The 2017 hormone therapy position statement of The North American Menopause Society. <i>Menopause.</i> 2017; <b>24</b>(7): 72853. <a target=xrefwindow id=d21666e2311 href="http://www.ncbi.nlm.nih.gov/pubmed/28650869">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2314 href="https://doi.org/10.1097/GME.0000000000000921">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727753897">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727215651"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2327 class=n-a></a>Marjoribanks J, Farquhar C, Roberts H, <i> et al.</i>: Long-term hormone therapy for perimenopausal and postmenopausal women. <i>Cochrane Database Syst Rev.</i> 2017; <b>1</b>: CD004143. <a target=xrefwindow id=d21666e2338 href="http://www.ncbi.nlm.nih.gov/pubmed/28093732">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2341 href="https://doi.org/10.1002/14651858.CD004143.pub5">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2345 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6465148">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727215651">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d21666e2358 class=n-a></a>Barrett-Connor E: Sex Differences in Coronary Heart Disease. <i>Circulation.</i> 1997; <b>95</b>(1): 25264. <a target=xrefwindow id=d21666e2366 href="https://doi.org/10.1161/01.CIR.95.1.252">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d21666e2375 class=n-a></a>Maxwell SRJ: Women and heart disease. <i>Basic Res Cardiol.</i> 1998; <b>93</b>(Supplement 2): s079s084. <a target=xrefwindow id=d21666e2383 href="https://doi.org/10.1007/s003950050225">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d21666e2393 class=n-a></a>Dubey RK, Imthurn B, Barton M, <i> et al.</i>: Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. <i>Cardiovasc Res.</i> 2005; <b>66</b>(2): 295306. <a target=xrefwindow id=d21666e2404 href="http://www.ncbi.nlm.nih.gov/pubmed/15820198">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2407 href="https://doi.org/10.1016/j.cardiores.2004.12.012">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d21666e2416 class=n-a></a>Salpeter SR, Cheng J, Thabane L, <i> et al.</i>: Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. <i>Am J Med.</i> 2009; <b>122</b>(11): 10161022.e1. <a target=xrefwindow id=d21666e2427 href="http://www.ncbi.nlm.nih.gov/pubmed/19854329">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2430 href="https://doi.org/10.1016/j.amjmed.2009.05.021">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d21666e2439 class=n-a></a>Guetta V, Cannon RO 3rd: Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. <i>Circulation.</i> 1996; <b>93</b>(10): 192837. <a target=xrefwindow id=d21666e2447 href="http://www.ncbi.nlm.nih.gov/pubmed/8635273">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2450 href="https://doi.org/10.1161/01.cir.93.10.1928">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d21666e2459 class=n-a></a>Fhraeus L: The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. <i>Obstet Gynecol.</i> 1988; <b>72</b>(5 Suppl): 18S22S. <a target=xrefwindow id=d21666e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/3173937">PubMed Abstract </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725436553"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2476 class=n-a></a>Miller VM, Lahr BD, Bailey KR, <i> et al.</i>: Longitudinal effects of menopausal hormone treatments on platelet characteristics and cell-derived microvesicles. <i>Platelets.</i> 2016; <b>27</b>(1): 3242. <a target=xrefwindow id=d21666e2487 href="http://www.ncbi.nlm.nih.gov/pubmed/25856160">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2490 href="https://doi.org/10.3109/09537104.2015.1023273">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2494 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4732432">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725436553">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d21666e2507 class=n-a></a>Westendorp IC, Bots ML, Grobbee DE, <i> et al.</i>: Menopausal status and distensibility of the common carotid artery. <i>Arterioscler Thromb Vasc Biol.</i> 1999; <b>19</b>(3): 7137. <a target=xrefwindow id=d21666e2518 href="http://www.ncbi.nlm.nih.gov/pubmed/10073978">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2521 href="https://doi.org/10.1161/01.ATV.19.3.713">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d21666e2531 class=n-a></a>Moreau KL, Meditz A, Deane KD, <i> et al.</i>: Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. <i>Am J Physiol Heart Circ Physiol.</i> 2012; <b>302</b>(5): H12118. <a target=xrefwindow id=d21666e2542 href="http://www.ncbi.nlm.nih.gov/pubmed/22245769">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2545 href="https://doi.org/10.1152/ajpheart.01065.2011">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2549 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3311456">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d21666e2558 class=n-a></a>Diano S, Horvath TL, Mor G, <i> et al.</i>: Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. <i>Menopause.</i> 1999; <b>6</b>(1): 2128. <a target=xrefwindow id=d21666e2569 href="http://www.ncbi.nlm.nih.gov/pubmed/10100176">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2572 href="https://doi.org/10.1097/00042192-199906010-00006">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d21666e2581 class=n-a></a>Joakimsen O, Bonaa KH, Stensland-Bugge E, <i> et al.</i>: Age and sex differences in the distribution and ultrasound morphology of carotid atherosclerosis: the Troms Study. <i>Arterioscler Thromb Vasc Biol.</i> 1999; <b>19</b>(12): 30073013. <a target=xrefwindow id=d21666e2592 href="http://www.ncbi.nlm.nih.gov/pubmed/10591682">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2595 href="https://doi.org/10.1161/01.ATV.19.12.3007">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733896587"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2604 class=n-a></a>Hevener AL, Zhou Z, Moore TM, <i> et al.</i>: The impact of ER action on muscle metabolism and insulin sensitivity - Strong enough for a man, made for a woman. <i>Mol Metab.</i> 2018; <b>15</b>: 2034. <a target=xrefwindow id=d21666e2615 href="http://www.ncbi.nlm.nih.gov/pubmed/30005878">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2618 href="https://doi.org/10.1016/j.molmet.2018.06.013">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2622 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6066787">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733896587">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d21666e2635 class=n-a></a>Ding J, Xu H, Yin X, <i> et al.</i>: Estrogen receptor  gene PvuII polymorphism and coronary artery disease: a meta-analysis of 21 studies. <i>J Zhejiang Univ Sci B.</i> 2014; <b>15</b>(3): 24355. <a target=xrefwindow id=d21666e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/24599688">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2649 href="https://doi.org/10.1631/jzus.B1300220">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2653 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3955911">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d21666e2662 class=n-a></a>Maffei L, Murata Y, Rochira V, <i> et al.</i>: Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. <i>J Clin Endocrinol Metab.</i> 2004; <b>89</b>(1): 6170. <a target=xrefwindow id=d21666e2673 href="http://www.ncbi.nlm.nih.gov/pubmed/14715828">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2676 href="https://doi.org/10.1210/jc.2003-030313">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d21666e2686 class=n-a></a>Rochira V, Carani C: Aromatase deficiency in men: a clinical perspective. <i>Nat Rev Endocrinol.</i> 2009; <b>5</b>(10): 55968. <a target=xrefwindow id=d21666e2694 href="http://www.ncbi.nlm.nih.gov/pubmed/19707181">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2697 href="https://doi.org/10.1038/nrendo.2009.176">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d21666e2706 class=n-a></a>Curatola AM, Huang K, Naftolin F: Dehydroepiandrosterone (DHEA) inhibition of monocyte binding by vascular endothelium is associated with sialylation of neural cell adhesion molecule. <i>Reprod Sci.</i> 2012; <b>19</b>(1): 8691. <a target=xrefwindow id=d21666e2714 href="http://www.ncbi.nlm.nih.gov/pubmed/22228741">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2717 href="https://doi.org/10.1177/1933719111414210">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3343126">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d21666e2729 class=n-a></a>Naftolin F, Mehr H, Fadiel A: Sex Steroids Block the Initiation of Atherosclerosis. <i>Reprod Sci.</i> 2016; <b>23</b>(12): 16205. <a target=xrefwindow id=d21666e2737 href="http://www.ncbi.nlm.nih.gov/pubmed/27821559">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2740 href="https://doi.org/10.1177/1933719116674078">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2743 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5933083">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d21666e2752 class=n-a></a>Santizo RA, Anderson S, Ye S, <i> et al.</i>: Effects of estrogen on leukocyte adhesion after transient forebrain ischemia. <i>Stroke.</i> 2000; <b>31</b>(9): 22315. <a target=xrefwindow id=d21666e2763 href="http://www.ncbi.nlm.nih.gov/pubmed/10978057">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2766 href="https://doi.org/10.1161/01.str.31.9.2231">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d21666e2775 class=n-a></a>Caulin-Glaser T, Watson CA, Pardi R, <i> et al.</i>: Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. <i>J Clin Invest.</i> 1996; <b>98</b>(1): 3642. <a target=xrefwindow id=d21666e2786 href="http://www.ncbi.nlm.nih.gov/pubmed/8690801">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2789 href="https://doi.org/10.1172/JCI118774">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2793 href="http://www.ncbi.nlm.nih.gov/pmc/articles/507398">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732788179"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2802 class=n-a></a>Chester RC, Kling JM, Manson JE: What the Women's Health Initiative has taught us about menopausal hormone therapy. <i>Clin Cardiol.</i> 2018; <b>41</b>(2): 24752. <a target=xrefwindow id=d21666e2810 href="http://www.ncbi.nlm.nih.gov/pubmed/29493798">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2813 href="https://doi.org/10.1002/clc.22891">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732788179">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d21666e2827 class=n-a></a>Grodstein F, Stampfer MJ, Manson JE, <i> et al.</i>: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. <i>N Engl J Med.</i> 1996; <b>335</b>(7): 45361. <a target=xrefwindow id=d21666e2838 href="http://www.ncbi.nlm.nih.gov/pubmed/8672166">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2841 href="https://doi.org/10.1056/NEJM199608153350701">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731260144"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2850 class=n-a></a>Bhupathiraju SN, Grodstein F, Rosner BA, <i> et al.</i>: Hormone Therapy Use and Risk of Chronic Disease in the Nurses' Health Study: A Comparative Analysis With the Women's Health Initiative. <i>Am J Epidemiol.</i> 2017; <b>186</b>(6): 696708. <a target=xrefwindow id=d21666e2861 href="http://www.ncbi.nlm.nih.gov/pubmed/28938710">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2864 href="https://doi.org/10.1093/aje/kwx131">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2868 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5860527">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731260144">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d21666e2881 class=n-a></a>Langer RD: Hormone replacement and the prevention of cardiovascular disease. <i>Am J Cardiol.</i> 2002; <b>89</b>(12A): 36E46E; discussion 46E. <a target=xrefwindow id=d21666e2889 href="http://www.ncbi.nlm.nih.gov/pubmed/12084403">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2892 href="https://doi.org/10.1016/s0002-9149(02)02411-6">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d21666e2901 class=n-a></a>Bush TL, Barrett-Connor E, Cowan LD, <i> et al.</i>: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. <i>Circulation.</i> 1987; <b>75</b>(6): 11029. <a target=xrefwindow id=d21666e2912 href="http://www.ncbi.nlm.nih.gov/pubmed/3568321">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2915 href="https://doi.org/10.1161/01.cir.75.6.1102">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d21666e2924 class=n-a></a>Grodstein F, Manson JE, Colditz GA, <i> et al.</i>: A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease. <i>Ann Intern Med.</i> 2000; <b>133</b>(12): 93341. <a target=xrefwindow id=d21666e2935 href="http://www.ncbi.nlm.nih.gov/pubmed/11119394">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2938 href="https://doi.org/10.7326/0003-4819-133-12-200012190-00008">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726586635"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e2947 class=n-a></a>Appiah D, Schreiner PJ, Demerath EW, <i> et al.</i>: Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis. <i>J Am Heart Assoc.</i> 2016; <b>5</b>(8): pii: e003769. <a target=xrefwindow id=d21666e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/27468929">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2961 href="https://doi.org/10.1161/JAHA.116.003769">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5015298">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726586635">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d21666e2979 class=n-a></a>Ebong IA, Watson KE, Goff DC Jr, <i> et al.</i>: Age at menopause and incident heart failure: the Multi-Ethnic Study of Atherosclerosis. <i>Menopause.</i> 2014; <b>21</b>(6): 58591. <a target=xrefwindow id=d21666e2990 href="http://www.ncbi.nlm.nih.gov/pubmed/24423934">PubMed Abstract </a> | <a target=xrefwindow id=d21666e2993 href="https://doi.org/10.1097/GME.0000000000000138">Publisher Full Text </a> | <a target=xrefwindow id=d21666e2997 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4031284">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d21666e3006 class=n-a></a>Salpeter SR, Buckley NS, Liu H, <i> et al.</i>: The cost-effectiveness of hormone therapy in younger and older postmenopausal women. <i>Am J Med.</i> 2009; <b>122</b>(1): 4252.e2. <a target=xrefwindow id=d21666e3017 href="http://www.ncbi.nlm.nih.gov/pubmed/19114171">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3020 href="https://doi.org/10.1016/j.amjmed.2008.07.026">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d21666e3029 class=n-a></a>Ge Q, Tian Q, Tseng H, <i> et al.</i>: Development of low-dose reproductive hormone therapies in China. <i>Gynecol Endocrinol.</i> 2006; <b>22</b>(11): 63645. <a target=xrefwindow id=d21666e3040 href="http://www.ncbi.nlm.nih.gov/pubmed/17145650">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3043 href="https://doi.org/10.1080/09513590601005912">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726855578"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3052 class=n-a></a>Lobo RA, Pickar JH, Stevenson JC, <i> et al.</i>: Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. <i>Atherosclerosis.</i> 2016; <b>254</b>: 28290. <a target=xrefwindow id=d21666e3063 href="http://www.ncbi.nlm.nih.gov/pubmed/27745704">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3066 href="https://doi.org/10.1016/j.atherosclerosis.2016.10.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726855578">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d21666e3079 class=n-a></a>Hulley S, Grady D, Bush T, <i> et al.</i>: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. <i>JAMA.</i> 1998; <b>280</b>(7): 60513. <a target=xrefwindow id=d21666e3090 href="http://www.ncbi.nlm.nih.gov/pubmed/9718051">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3093 href="https://doi.org/10.1001/jama.280.7.605">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d21666e3102 class=n-a></a>Rossouw JE, Anderson GL, Prentice RL, <i> et al.</i>: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. <i>JAMA.</i> 2002; <b>288</b>(3): 32133. <a target=xrefwindow id=d21666e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/12117397">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3116 href="https://doi.org/10.1001/jama.288.3.321">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d21666e3126 class=n-a></a>Grodstein F, Manson JE, Stampfer MJ: Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. <i>J Womens Health (Larchmt).</i> 2006; <b>15</b>(1): 3544. <a target=xrefwindow id=d21666e3134 href="http://www.ncbi.nlm.nih.gov/pubmed/16417416">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3137 href="https://doi.org/10.1089/jwh.2006.15.35">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d21666e3146 class=n-a></a>Reslan OM, Khalil RA: Vascular effects of estrogenic menopausal hormone therapy. <i>Rev Recent Clin Trials.</i> 2012; <b>7</b>(1): 4770. <a target=xrefwindow id=d21666e3154 href="http://www.ncbi.nlm.nih.gov/pubmed/21864249">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3157 href="https://doi.org/10.2174/157488712799363253">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3160 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3227781">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d21666e3169 class=n-a></a>Tan O, Harman SM, Naftolin F: What can we learn from design faults in the Women's Health Initiative randomized clinical trial? <i>Bull NYU Hosp Jt Dis.</i> 2009; <b>67</b>(2): 2269. <a target=xrefwindow id=d21666e3177 href="http://www.ncbi.nlm.nih.gov/pubmed/19583558">PubMed Abstract </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d21666e3186 class=n-a></a>Naftolin F, Taylor HS, Karas R, <i> et al.</i>: The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. <i>Fertil Steril.</i> 2004; <b>81</b>(6): 1498501. <a target=xrefwindow id=d21666e3197 href="http://www.ncbi.nlm.nih.gov/pubmed/15193467">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3200 href="https://doi.org/10.1016/j.fertnstert.2004.02.095">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725357084"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3209 class=n-a></a>Avis NE, Crawford SL, Greendale G, <i> et al.</i>: Duration of menopausal vasomotor symptoms over the menopause transition. <i>JAMA Intern Med.</i> 2015; <b>175</b>(4): 5319. <a target=xrefwindow id=d21666e3220 href="http://www.ncbi.nlm.nih.gov/pubmed/25686030">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3223 href="https://doi.org/10.1001/jamainternmed.2014.8063">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4433164">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725357084">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d21666e3240 class=n-a></a>Prentice RL, Manson JE, Langer RD, <i> et al.</i>: Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. <i>Am J Epidemiol.</i> 2009; <b>170</b>(1): 1223. <a target=xrefwindow id=d21666e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/19468079">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3254 href="https://doi.org/10.1093/aje/kwp115">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3258 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2733042">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d21666e3268 class=n-a></a>Langer RD, Simon JA, Pines A, <i> et al.</i>: Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. <i>Menopause.</i> 2017; <b>24</b>(10): 110112. <a target=xrefwindow id=d21666e3279 href="http://www.ncbi.nlm.nih.gov/pubmed/28872490">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3282 href="https://doi.org/10.1097/GME.0000000000000983">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3291 class=n-a></a>Hsia J, Langer RD, Manson JE, <i> et al.</i>: Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. <i>Arch Intern Med.</i> 2006; <b>166</b>(3): 35765. <a target=xrefwindow id=d21666e3302 href="http://www.ncbi.nlm.nih.gov/pubmed/16476878">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3305 href="https://doi.org/10.1001/archinte.166.3.357">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13400">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1074767"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3318 class=n-a></a>Rossouw JE, Prentice RL, Manson JE, <i> et al.</i>: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. <i>JAMA.</i> 2007; <b>297</b>(13): 146577. <a target=xrefwindow id=d21666e3329 href="http://www.ncbi.nlm.nih.gov/pubmed/17405972">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3332 href="https://doi.org/10.1001/jama.297.13.1465">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1074767">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d21666e3345 class=n-a></a>Saito Y, Sakamoto H, MacLusky NJ, <i> et al.</i>: Gap junctions and myometrial steroid hormone receptors in pregnant and postpartum rats: a possible cellular basis for the progesterone withdrawal hypothesis. <i>Am J Obstet Gynecol.</i> 1985; <b>151</b>(6): 80512. <a target=xrefwindow id=d21666e3356 href="http://www.ncbi.nlm.nih.gov/pubmed/3976793">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3359 href="https://doi.org/10.1016/0002-9378(85)90525-3">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d21666e3368 class=n-a></a>Chlebowski RT, Rohan TE, Manson JE, <i> et al.</i>: Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncol.</i> 2015; <b>1</b>(3): 296305. <a target=xrefwindow id=d21666e3379 href="http://www.ncbi.nlm.nih.gov/pubmed/26181174">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3382 href="https://doi.org/10.1001/jamaoncol.2015.0494">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d21666e3391 class=n-a></a>Santen RJ: Risk of breast cancer with progestins: critical assessment of current data. <i>Steroids.</i> 2003; <b>68</b>(1013): 95364. <a target=xrefwindow id=d21666e3399 href="http://www.ncbi.nlm.nih.gov/pubmed/14667988">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3402 href="https://doi.org/10.1016/s0039-128x(03)00138-7">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718160743"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3412 class=n-a></a>Gurney EP, Nachtigall MJ, Nachtigall LE, <i> et al.</i>: The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. <i>J Steroid Biochem Mol Biol.</i> 2014; <b>142</b>: 411. <a target=xrefwindow id=d21666e3423 href="http://www.ncbi.nlm.nih.gov/pubmed/24172877">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3426 href="https://doi.org/10.1016/j.jsbmb.2013.10.009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718160743">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d21666e3439 class=n-a></a>Stanczyk FZ, Bhavnani BR: Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? <i>J Steroid Biochem Mol Biol.</i> 2014; <b>142</b>: 308. <a target=xrefwindow id=d21666e3447 href="http://www.ncbi.nlm.nih.gov/pubmed/24291402">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3450 href="https://doi.org/10.1016/j.jsbmb.2013.11.011">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d21666e3459 class=n-a></a>Clarkson TB, Anthony MS, Jerome CP: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. <i>J Clin Endocrinol Metab.</i> 1998; <b>83</b>(3): 7216. <a target=xrefwindow id=d21666e3467 href="http://www.ncbi.nlm.nih.gov/pubmed/9506715">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3470 href="https://doi.org/10.1210/jcem.83.3.4617">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726995166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3479 class=n-a></a>Gudmundsson A, Aspelund T, Sigurdsson G, <i> et al.</i>: Long-Term Hormone Replacement Therapy Is Associated with Low Coronary Artery Calcium Levels in a Cohort of Older Women: The Age, Gene/Environment Susceptibility-Reykjavik Study. <i>J Am Geriatr Soc.</i> 2017; <b>65</b>(1): 2006. <a target=xrefwindow id=d21666e3490 href="http://www.ncbi.nlm.nih.gov/pubmed/27861721">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3493 href="https://doi.org/10.1111/jgs.14461">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5258833">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726995166">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731115275"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3510 class=n-a></a>Manson JE, Aragaki AK, Rossouw JE, <i> et al.</i>: Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. <i>JAMA.</i> 2017; <b>318</b>(10): 92738. <a target=xrefwindow id=d21666e3521 href="http://www.ncbi.nlm.nih.gov/pubmed/28898378">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3524 href="https://doi.org/10.1001/jama.2017.11217">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5728370">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731115275">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d21666e3541 class=n-a></a>Mikkola TS, Clarkson TB, Notelovitz M: Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? <i>Ann Med.</i> 2004; <b>36</b>(6): 40213. <a target=xrefwindow id=d21666e3549 href="http://www.ncbi.nlm.nih.gov/pubmed/15513292">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3552 href="https://doi.org/10.1080/07853890410035430">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d21666e3562 class=n-a></a>Williams JK, Anthony MS, Honor EK, <i> et al.</i>: Regression of atherosclerosis in female monkeys. <i>Arterioscler Thromb Vasc Biol.</i> 1995; <b>15</b>(7): 82736. <a target=xrefwindow id=d21666e3573 href="http://www.ncbi.nlm.nih.gov/pubmed/7600113">PubMed Abstract </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d21666e3582 class=n-a></a>Choi SD, Steinberg EM, Lee HH, <i> et al.</i>: The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. <i>Menopause.</i> 2011; <b>18</b>(2): 2306. <a target=xrefwindow id=d21666e3593 href="http://www.ncbi.nlm.nih.gov/pubmed/21341398">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3596 href="https://doi.org/10.1097/gme.0b013e3181e97344">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d21666e3605 class=n-a></a>Manson JE: The 'timing hypothesis' for estrogen therapy in menopausal symptom management. <i>Womens Health (Lond).</i> 2015; <b>11</b>(4): 43740. <a target=xrefwindow id=d21666e3613 href="http://www.ncbi.nlm.nih.gov/pubmed/26237097">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3616 href="https://doi.org/10.2217/WHE.15.24">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d21666e3625 class=n-a></a>Clarkson TB, Melndez GC, Appt SE: Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. <i>Menopause.</i> 2013; <b>20</b>(3): 34253. <a target=xrefwindow id=d21666e3633 href="http://www.ncbi.nlm.nih.gov/pubmed/23435033">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3636 href="https://doi.org/10.1097/GME.0b013e3182843aad">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726253942"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d21666e3645 class=n-a></a>Hodis HN, Mack WJ, Henderson VW, <i> et al.</i>: Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. <i>N Engl J Med.</i> 2016; <b>374</b>(13): 122131. <a target=xrefwindow id=d21666e3656 href="http://www.ncbi.nlm.nih.gov/pubmed/27028912">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3659 href="https://doi.org/10.1056/NEJMoa1505241">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4921205">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726253942">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d21666e3676 class=n-a></a>ACOG Practice Bulletin No. 141: management of menopausal symptoms. <i>Obstet Gynecol.</i> 2014; <b>123</b>(1): 20216. <a target=xrefwindow id=d21666e3684 href="http://www.ncbi.nlm.nih.gov/pubmed/24463691">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3687 href="https://doi.org/10.1097/01.AOG.0000441353.20693.78">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d21666e3697 class=n-a></a>Sood R, Faubion SS, Kuhle CL, <i> et al.</i>: Prescribing menopausal hormone therapy: an evidence-based approach. <i>Int J Womens Health.</i> 2014; <b>6</b>: 4757. <a target=xrefwindow id=d21666e3708 href="http://www.ncbi.nlm.nih.gov/pubmed/24474847">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3711 href="https://doi.org/10.2147/IJWH.S38342">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3715 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3897322">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d21666e3724 class=n-a></a>Santoro N, Lasley B, McConnell D, <i> et al.</i>: Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. <i>J Clin Endocrinol Metab.</i> 2004; <b>89</b>(6): 262231. <a target=xrefwindow id=d21666e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/15181033">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3738 href="https://doi.org/10.1210/jc.2003-031578">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d21666e3747 class=n-a></a>US Food and Drug Administration: Menopause and Hormones: Common questions. 2017. <a target=xrefwindow id=d21666e3749 href="http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118624.htm">Reference Source</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d21666e3758 class=n-a></a>Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. <i>Ann Intern Med.</i> 2001; <b>135</b>(1): 18. <a target=xrefwindow id=d21666e3766 href="http://www.ncbi.nlm.nih.gov/pubmed/11434726">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3769 href="https://doi.org/10.7326/0003-4819-135-1-200107030-00003">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d21666e3778 class=n-a></a>Chilvers CE, Knibb RC, Armstrong SJ, <i> et al.</i>: Post menopausal hormone replacement therapy and risk of acute myocardial infarction--a case control study of women in the East Midlands, UK. <i>Eur Heart J.</i> 2003; <b>24</b>(24): 2197205. <a target=xrefwindow id=d21666e3789 href="http://www.ncbi.nlm.nih.gov/pubmed/14659771">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3792 href="https://doi.org/10.1016/j.ehj.2003.09.019">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d21666e3801 class=n-a></a>Toh S, Hernndez-Daz S, Logan R, <i> et al.</i>: Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. <i>Ann Intern Med.</i> 2010; <b>152</b>(4): 2117. <a target=xrefwindow id=d21666e3812 href="http://www.ncbi.nlm.nih.gov/pubmed/20157135">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3815 href="https://doi.org/10.7326/0003-4819-152-4-201002160-00005">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3819 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2936769">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d21666e3829 class=n-a></a>Harman SM, Vittinghoff E, Brinton EA, <i> et al.</i>: Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. <i>Am J Med.</i> 2011; <b>124</b>(3): 199205. <a target=xrefwindow id=d21666e3840 href="http://www.ncbi.nlm.nih.gov/pubmed/21396500">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3843 href="https://doi.org/10.1016/j.amjmed.2010.09.021">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3107840">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d21666e3856 class=n-a></a>Harman SM, Brinton EA, Cedars M, <i> et al.</i>: KEEPS: The Kronos Early Estrogen Prevention Study. <i>Climacteric.</i> 2005; <b>8</b>(1): 312. <a target=xrefwindow id=d21666e3867 href="http://www.ncbi.nlm.nih.gov/pubmed/15804727">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3870 href="https://doi.org/10.1080/13697130500042417">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d21666e3879 class=n-a></a>Lindsay R: Hormones and bone health in postmenopausal women. <i>Endocrine.</i> 2004; <b>24</b>(3): 22330. <a target=xrefwindow id=d21666e3887 href="http://www.ncbi.nlm.nih.gov/pubmed/15542889">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3890 href="https://doi.org/10.1385/ENDO:24:3:223">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d21666e3899 class=n-a></a>Schenker JG, Sciarra JJ, Mettler L, <i> et al.</i>: Reproductive Medicine for Clinical Practice. Springer International Publishing. 2018; 191201. <a target=xrefwindow id=d21666e3904 href="https://doi.org/10.1007/978-3-319-78009-2">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d21666e3913 class=n-a></a>Kantarci K, Tosakulwong N, Lesnick TG, <i> et al.</i>: Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology.</i> 2018; <b>19</b>(16): e1404e1412. <a target=xrefwindow id=d21666e3924 href="http://www.ncbi.nlm.nih.gov/pubmed/29661902">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3927 href="https://doi.org/10.1212/WNL.0000000000005325">Publisher Full Text </a> | <a target=xrefwindow id=d21666e3931 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5902783">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d21666e3940 class=n-a></a>Naftolin F, Friedenthal J, Blakemore J, <i> et al.</i>: Hormone therapy and ovarian cancer. <i>Lancet.</i> 2015; <b>386</b>(9998): 1037. <a target=xrefwindow id=d21666e3951 href="http://www.ncbi.nlm.nih.gov/pubmed/26382990">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3954 href="https://doi.org/10.1016/S0140-6736(15)00137-3">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d21666e3964 class=n-a></a>Schenker JG, Sciarra JJ, Mettler L, <i> et al.</i>: Reproductive Medicine for Clinical Practice. Springer International Publishing. 2018; 155163. <a target=xrefwindow id=d21666e3969 href="https://doi.org/10.1007/978-3-319-78009-2">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d21666e3978 class=n-a></a>Devi G, Sugiguchi F, Pedersen AT, <i> et al.</i>: Current attitudes on self-use and prescription of hormone therapy among New York City gynaecologists. <i>Menopause Int.</i> 2013; <b>19</b>(3): 1216. <a target=xrefwindow id=d21666e3989 href="http://www.ncbi.nlm.nih.gov/pubmed/23761315">PubMed Abstract </a> | <a target=xrefwindow id=d21666e3992 href="https://doi.org/10.1177/1754045313478941">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 03 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1576.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1576.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Interdisciplinary Program in Menopausal Medicine, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA<br/> <p> <div class=margin-bottom> Frederick Naftolin <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Jenna Friedenthal <br/> <span>Roles: </span> Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Richard Nachtigall <br/> <span>Roles: </span> Writing  Review & Editing </div> <div class=margin-bottom> Lila Nachtigall <br/> <span>Roles: </span> Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1576/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 03 Sep 2019, 8:1576 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15548.1">https://doi.org/10.12688/f1000research.15548.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Naftolin F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16960 data-id=15548 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15548.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1576/v1/pdf?article_uuid=cc9fba0b-e981-42d7-9a37-f0aa6917127a" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15548.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Naftolin F, Friedenthal J, Nachtigall R and Nachtigall L. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1576 (<a href="https://doi.org/10.12688/f1000research.15548.1" target=_blank>https://doi.org/10.12688/f1000research.15548.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15548 id=mobile-track-article-signin-15548 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15548?target=/articles/8-1576.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16960 /> <input name=articleId type=hidden value=15548 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Leanne Groban</strong>, Departments of Anesthesiology and Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>James A. Simon</strong>, Department of Obstetrics and Gynecology, George Washington University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Antonio Cano</strong>, Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 03 Sep 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1576.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1576.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55795-52749></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55796-52748></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=55797-52750></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1576/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>03 Sep 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Leanne Groban</strong>, Departments of Anesthesiology and Internal Medicine-Molecular Medicine, Wake Forest School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>James A. Simon</strong>, Department of Obstetrics and Gynecology, George Washington University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Antonio Cano</strong>, Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1576.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1576/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Cardiovascular health and the menopausal...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1576/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1576/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1576/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Naftolin F et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1576/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1576",
            templates : {
                twitter : "Cardiovascular health and the menopausal woman: the role of estrogen.... Naftolin F et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1576/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15548/16960")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16960");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "52748": 1,
                           "52749": 0,
                           "52750": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "4cec356b-7b46-4b40-b3f4-456a73e0a861";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1576.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1576.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1576.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1576.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1576.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>